RxDoctor Payments Data

Sunil Reddy, MD

Clinical Cardiac Electrophysiology · McKinney, TXNPI 1760624928

Payments from drug & device makers

$45,274in general payments, 2019–2025

Across 560 payments — averaging $80.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$19K
  • Biosense Webster, Inc.$7K
  • Medtronic$5K
  • Boston Scientific$3K
  • Biotronik Inc.$3K
  • Atricure, Inc.$2K
  • plus $6K from 34 others

What the payments were for

  • Consulting fees$4,72514%
  • Travel & lodging$5,34416%
  • Food & beverage$22,86868%
  • Education$4561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,274 in reported general payments places this provider in the 50th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$457,850
Medicare patients
665
Services billed
4,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban349$319,976
XareltoRivaroxaban64$51,162
MultaqDronedarone Hcl41$41,980
EntrestoSacubitril/Valsartan17$20,693
Flecainide Acetate145$4,682
Amiodarone Hcl206$3,009
Metoprolol Succinate162$1,198
Mexiletine Hcl15$1,168
SotalolSotalol Hcl38$809
Valsartan18$328
Losartan Potassium37$303
Furosemide53$251
Amlodipine Besylate49$233
Carvedilol25$200
Potassium Chloride23$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$699$319,976349 claims
Johnson & JohnsonXarelto$216$51,16264 claims
Sanofi-aventis U.S. LLCMultaq$79$41,98041 claims
NovartisEntresto$316$20,69317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in McKinney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →